



Group Reporting Pack			
CP Pharma (Schweiz) AG		(All Amount in Local Currency)	
Balance Sheet as per Group accounting policies			
		As at 31.03.2024	As at 31.03.2023
SOURCES OF FUNDS			
SHAREHOLDERS' FUNDS			
Share capital			
Equity share capital		(250'000.00)	(250'000.00)
Preference share capital		-	-
Reserves and surplus		125'465.09	106'203.36
		(124'534.91)	(143'796.64)
LOAN FUNDS			
Secured loans		-	-
Unsecured loans		-	-
		-	-
DEFERRED TAX LIABILITY			
		-	-
TOTAL OF SOURCES OF FUNDS		(124'534.91)	(143'796.64)
APPLICATION OF FUNDS			
FIXED ASSETS			
Gross block		-	-
Accumulated depreciation		-	-
Net block		-	-
Capital work-in-progress and advances		-	-
		-	-
INVESTMENTS			
		-	-
CURRENT ASSETS, LOANS AND ADVANCES			
Inventories		-	-
Sundry debtors		39.70	119.00
Cash and bank balances		142'194.85	146'677.28
Loans and advances		-	-
		142'234.55	146'796.28
CURRENT LIABILITIES AND PROVISIONS			
Current Liabilities		(17'700.00)	(3'000.00)
Provisions		-	-
		(17'700.00)	(3'000.00)
NET CURRENT ASSETS		124'534.55	143'796.28
Misc Exps to the extent not w/off			
Minority Interest			
TOTAL OF APPLICATION OF FUNDS		124'534.55	143'796.28
Difference in Balancesheet		(0)	(0)
For Treucontrol Ltd		For CP Pharma (Schweiz) AG	
Chartered Accountants		Grafenauweg 6	
Firm Registration No.		6300 Zug	
CH-170.3.018.061-6			
			
Partner		Adrian Ashurst	
Membership No. 100055			
Place: Egg		Place: Zug	
Date: April 25, 2024		Date: April 25, 2024	

Statement of Profit and Loss as per Group accounting policies

	Adjusted for Ind AS				
	For the quarter ended			YTD ended	
	00. Jan 00	00. Jan 00	00. Jan 00	31. Mär 24	31. Mär 23
INCOME					
Sales and services	-	-	-	-	-
Less: Excise Duty	-	-	-	-	-
Other income	-	-	-	-	(1'000.00)
	-	-	-	-	(1'000.00)
EXPENDITURE					
Materials consumed	-	-	-	-	-
Purchase of Stock In Trade	-	-	-	-	-
(Increase) / decrease in inventories	-	-	-	-	-
Employee Benefit Expense	-	-	-	-	-
Operating and other expenses	-	-	-	18'790.00	4'545.00
Depreciation / Amortisation	-	-	-	-	-
Financing cost	-	-	-	121.08	120.11
Exchange rate differences - loss / (gain)	-	-	-	-	-
VRS	-	-	-	-	-
	-	-	-	18'911.08	4'665.11
PROFIT BEFORE TAX AND EXTRAORDINARY ITEM	-	-	-	18'911.08	3'665.11
Add / (Less) : Exceptional items Loss / (Gain)	-	-	-	-	-
PROFIT BEFORE TAX	-	-	-	18'911.08	3'665.11
Provision for tax					
- Current	-	-	-	350.65	29.95
- Fringe benefit Tax	-	-	-	-	-
- Deferred	-	-	-	-	-
NET PROFIT AFTER TAX FOR THE YEAR	-	-	-	19'261.73	3'695.06
Minority Interest	-	-	-	-	-
ExChange difference on foreign currency investments	-	-	-	-	-
Movement on Deferred tax relating to pension deficit	-	-	-	-	-
Pension charge	-	-	-	-	-
PAT after adjustments	-	-	-	19'261.73	3'695.06
PROFIT AVAILABLE FOR APPROPRIATION	-	-	-	19'261.73	3'695.06
APPROPRIATIONS					
Interim dividend on equity shares	-	-	-	-	-
Interim dividend on preference shares	-	-	-	-	-
Proposed dividend on preference shares	-	-	-	-	-
Proposed dividend on equity shares	-	-	-	-	-
Tax on dividend	-	-	-	-	-
Transfer to debenture redemption reserve	-	-	-	-	-
Transfer to capital redemption reserve	-	-	-	-	-
Transfer to general reserve	-	-	-	-	-
PROFIT AND LOSS ACCOUNT, end of year	-	-	-	19'261.73	3'695.06
	-	-	-	19'261.73	3'695.06

For Treucontrol Ltd
 Chartered Accountants
 Firm Registration No.
 CH-170.3.018.061-6

fandou

Partner
 Membership No. 100055
 Place: Egg
 Date: April 25, 2024

For CP Pharma (Schweiz) AG
 Grafenauweg 6
 6300 Zug

Adrian Ashurst

Adrian Ashurst
 Place: Egg
 Date: April 25, 2024